Indaptus Therapeutics Presents Encouraging Interim Safety Data From Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Indaptus Therapeutics在海豐國際2024年會議上展示了Decoy20階段1臨床試驗鼓舞人心的中期安全數據
Indaptus Therapeutics Presents Encouraging Interim Safety Data From Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Indaptus Therapeutics在海豐國際2024年會議上展示了Decoy20階段1臨床試驗鼓舞人心的中期安全數據
使用瀏覽器的分享功能,分享給你的好友吧